Taking pravastatin for 3 months didn’t raise or lower average blood sugar or long-term blood sugar control in people with early kidney disease who don’t have diabetes.
Scientific Claim
Pravastatin at 40 mg/day for 12 weeks does not significantly alter fasting plasma glucose or HbA1c levels in non-diabetic patients with chronic kidney disease stages 1–3, with mean differences of −0.1 mmol/L (P=0.39) and 0.75 mmol/mol (P=0.23), respectively, compared to placebo.
Original Statement
“Mean fasting P-glucose was 5.6 mmol/l (SEM ±0.1) and 5.5 mmol/l (SEM ±0.1) following treatment with Pravastatin and placebo, respectively, with a non-significant difference of −0.1 mmol/l (95% CI −0.3 to 0.1, P = 0.39). Mean HbA1c was 35.0 mmol/mol (SEM ±0.83) and 35.5 mmol/mol (SEM ±1.21) following treatment with Pravastatin and placebo, respectively, with a non-significant difference between treatments of 0.75 mmol/mol (SE ±0.60, 95% CI −0.56 to 2.06, P = 0.23).”
Evidence Quality Assessment
Claim Status
appropriately stated
Study Design Support
Design supports claim
Appropriate Language Strength
probability
Can suggest probability/likelihood
Assessment Explanation
The RCT design supports causal inference, but small sample size and borderline p-values warrant cautious interpretation. Probabilistic language is appropriate to reflect uncertainty.
More Accurate Statement
“Pravastatin at 40 mg/day for 12 weeks likely does not significantly alter fasting plasma glucose or HbA1c levels in non-diabetic patients with chronic kidney disease stages 1–3, with mean differences of −0.1 mmol/L (P=0.39) and 0.75 mmol/mol (P=0.23), respectively, compared to placebo.”
Gold Standard Evidence Needed
According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.
Systematic Review & Meta-AnalysisLevel 1aWhether pravastatin consistently has no effect on HbA1c and fasting glucose across diverse CKD populations and longer durations.
Whether pravastatin consistently has no effect on HbA1c and fasting glucose across diverse CKD populations and longer durations.
What This Would Prove
Whether pravastatin consistently has no effect on HbA1c and fasting glucose across diverse CKD populations and longer durations.
Ideal Study Design
Meta-analysis of RCTs comparing pravastatin (40 mg/day) to placebo in non-diabetic CKD stages 1–3 patients, with HbA1c and fasting glucose as primary endpoints, minimum 12-week duration, and total n≥500.
Limitation: Cannot assess individual variability or long-term diabetes incidence.
Randomized Controlled TrialLevel 1bIn EvidenceCausal effect of pravastatin on HbA1c and fasting glucose in CKD patients with adequate power.
Causal effect of pravastatin on HbA1c and fasting glucose in CKD patients with adequate power.
What This Would Prove
Causal effect of pravastatin on HbA1c and fasting glucose in CKD patients with adequate power.
Ideal Study Design
Double-blind RCT of 200+ non-diabetic CKD stage 1–3 patients randomized to pravastatin 40 mg/day vs. placebo for 24 weeks, with HbA1c and fasting glucose measured at baseline, 12, and 24 weeks, adjusting for baseline eGFR and BMI.
Limitation: Does not capture effects beyond 6 months or impact on diabetes diagnosis.
Prospective Cohort StudyLevel 2bLong-term association between pravastatin use and progression to prediabetes or diabetes in CKD patients.
Long-term association between pravastatin use and progression to prediabetes or diabetes in CKD patients.
What This Would Prove
Long-term association between pravastatin use and progression to prediabetes or diabetes in CKD patients.
Ideal Study Design
Prospective cohort of 1000+ non-diabetic CKD stage 1–3 patients followed for 5 years, comparing HbA1c trajectories in those taking pravastatin vs. those not, with annual OGTT and adjustment for confounders.
Limitation: Cannot prove causation due to potential confounding by indication.
Evidence from Studies
Supporting (1)
This study gave 13 people with early kidney disease 40 mg of pravastatin daily for 12 weeks and checked their blood sugar and HbA1c before and after. It found no real change in either, meaning the drug didn’t raise or lower their blood sugar levels — just like the claim says.